Flying under the radar: the immunobiology of hepatitis C.

The hepatitis C virus (HCV) is a remarkably successful pathogen, establishing persistent infection in more than two-thirds of those who contract it. Its success is related to its abilities to blunt innate antiviral pathways and to evade adaptive immune responses. These two themes may be related. We propose that HCV takes advantage of the impaired innate response to delay the organization of an effective adaptive immune attack. The tolerogenic liver environment may provide cover, prolonging this delay. HCV's error-prone replication strategy permits rapid evolution under immune pressure. Persistent high levels of viral antigens may contribute to immune exhaustion. Finally, the virus may benefit from the efficient enlistment of memory T and B cells in the pursuit of a moving target.

[1]  C. Rice,et al.  Foxp3+CD4+CD25+ T cells control virus-specific memory T cells in chimpanzees that recovered from hepatitis C. , 2006, Blood.

[2]  O. Pybus,et al.  Dominant influence of an HLA‐B27 restricted CD8+ T cell response in mediating HCV clearance and evolution , 2006, Hepatology.

[3]  X. Mariette,et al.  Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. , 2002, The New England journal of medicine.

[4]  M. Brook,et al.  Treatment of hepatitis. , 1988, The Journal of hospital infection.

[5]  G. Missale,et al.  The Impairment of CD8 Responses Limits the Selection of Escape Mutations in Acute Hepatitis C Virus Infection1 , 2005, The Journal of Immunology.

[6]  F. Chisari,et al.  Oscillating CD8(+) T cell effector functions after antigen recognition in the liver. , 2005, Immunity.

[7]  D. Accapezzato,et al.  Hepatic expansion of a virus-specific regulatory CD8+ T cell population in chronic hepatitis C virus infection , 2004 .

[8]  A. Bertoletti,et al.  The influence of T cell cross‐reactivity on HCV‐peptide specific human T cell response , 2006, Hepatology.

[9]  J. Prieto,et al.  Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses , 2003, Journal of Virology.

[10]  Grégoire Altan-Bonnet,et al.  Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell–dendritic cell interaction , 2006, Nature.

[11]  M. Mayo Extrahepatic manifestations of hepatitis C infection. , 2003, The American journal of the medical sciences.

[12]  H. Blum,et al.  Intrahepatic CD8+ T‐cell failure during chronic hepatitis C virus infection , 2005, Hepatology.

[13]  L. Romics,et al.  Hepatitis C Virus Core and Nonstructural Protein 3 Proteins Induce Pro- and Anti-inflammatory Cytokines and Inhibit Dendritic Cell Differentiation1 , 2003, The Journal of Immunology.

[14]  O. Pybus,et al.  Do antiviral CD8+ T cells select hepatitis C virus escape mutants? Analysis in diverse epitopes targeted by human intrahepatic CD8+ T lymphocytes , 2006, Journal of viral hepatitis.

[15]  G. Lauer,et al.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C , 2005, Hepatology.

[16]  C. Rice,et al.  Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Robert S. Brown Hepatitis C and liver transplantation , 2005, Nature.

[18]  B. Rehermann,et al.  The liver as an immunological organ , 2006, Hepatology.

[19]  William M. Lee,et al.  Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  M. Shapiro,et al.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[21]  N. Afdhal,et al.  Hepatic CD1d Expression in Hepatitis C Virus Infection and Recognition by Resident Proinflammatory CD1d-Reactive T Cells1 , 2004, The Journal of Immunology.

[22]  D. Tyrrell,et al.  Induction of Primary Human T Cell Responses against Hepatitis C Virus-Derived Antigens NS3 or Core by Autologous Dendritic Cells Expressing Hepatitis C Virus Antigens: Potential for Vaccine and Immunotherapy1 , 2006, The Journal of Immunology.

[23]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[24]  Andrew H Talal,et al.  Plasma chemokine levels correlate with the outcome of antiviral therapy in patients with hepatitis C. , 2005, Blood.

[25]  K. Reddy,et al.  T‐cell response relative to genotype and ethnicity during antiviral therapy for chronic hepatitis C , 2005, Hepatology.

[26]  L. Wodicka,et al.  Genomic analysis of the host response to hepatitis C virus infection , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Deborah Chavez,et al.  Genomic response to interferon‐α in chimpanzees: Implications of rapid downregulation for hepatitis C kinetics , 2006, Hepatology.

[28]  M. Alter,et al.  Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. , 1996, JAMA.

[29]  Y. Tominaga,et al.  Expression of IFN-inducible protein-10 in chronic hepatitis. , 1997, Journal of immunology.

[30]  M. Davis,et al.  Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Raymond M. Welsh,et al.  No one is naive: the significance of heterologous T-cell immunity , 2002, Nature Reviews Immunology.

[32]  N. Gruener,et al.  Detection of functionally altered hepatitis C virus‐specific CD4+ T cells in acute and chronic hepatitis C , 2003, Hepatology.

[33]  F. Chisari,et al.  Determinants of Viral Clearance and Persistence during Acute Hepatitis C Virus Infection , 2001, The Journal of experimental medicine.

[34]  B. Rehermann,et al.  Hepatitis C virus infection: when silence is deception. , 2003, Trends in immunology.

[35]  Chronic hepatitis C virus infection established and maintained in chimpanzees independent of dendritic cell impairment , 2003 .

[36]  J. Bennink,et al.  Cross-Reactivity between Hepatitis C Virus and Influenza A Virus Determinant-Specific Cytotoxic T Cells , 2001, Journal of Virology.

[37]  Stanley M Lemon,et al.  Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Stuart C. Ray,et al.  Divergent and convergent evolution after a common-source outbreak of hepatitis C virus , 2005, The Journal of experimental medicine.

[39]  M. Alter,et al.  Epidemiology of Hepatitis C: Geographic Differences and Temporal Trends , 2000, Seminars in liver disease.

[40]  E. Shin,et al.  Private aspects of heterologous immunity , 2005, The Journal of experimental medicine.

[41]  Bin Li,et al.  Full-Breadth Analysis of CD8+ T-Cell Responses in Acute Hepatitis C Virus Infection and Early Therapy , 2005, Journal of Virology.

[42]  T. Layden,et al.  Hepatitis C Kinetics: Mathematical Modeling of Viral Response to Therapy , 2000, Seminars in liver disease.

[43]  R. Bartenschlager,et al.  Interferon‐γ inhibits replication of subgenomic and genomic hepatitis C virus RNAs , 2002 .

[44]  R. Welsh,et al.  CD8 T cell responses to viral infections in sequence , 2004, Cellular microbiology.

[45]  S. Kalams,et al.  Limited T Cell Receptor Diversity of HCV-specific T Cell Responses Is Associated with CTL Escape , 2004, The Journal of experimental medicine.

[46]  D. R. Taylor,et al.  Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. , 1999, Science.

[47]  R. Doms,et al.  Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR , 2003, Journal of Virology.

[48]  Shizuo Akira,et al.  Innate immune recognition of viral infection , 2006, Nature Immunology.

[49]  C. Walker,et al.  Mutational escape from CD8+ T cell immunity , 2005, The Journal of experimental medicine.

[50]  B. Bartosch,et al.  C-type Lectins L-SIGN and DC-SIGN Capture and Transmit Infectious Hepatitis C Virus Pseudotype Particles* , 2004, Journal of Biological Chemistry.

[51]  Zhijian J. Chen,et al.  Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3 , 2005, Cell.

[52]  J. Bukh A critical role for the chimpanzee model in the study of hepatitis C , 2004, Hepatology.

[53]  Todd M. Allen,et al.  High resolution analysis of cellular immune responses in resolved and persistent hepatitis C virus infection. , 2004, Gastroenterology.

[54]  R. Steinman,et al.  Dendritic cell maturation by innate lymphocytes , 2005, The Journal of experimental medicine.

[55]  N. Hayashi,et al.  Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals. , 1999, Journal of immunology.

[56]  H. Agut,et al.  Differential distribution and internal translation efficiency of hepatitis C virus quasispecies present in dendritic and liver cells. , 2003, Blood.

[57]  Charles M. Rice,et al.  Unravelling hepatitis C virus replication from genome to function , 2005, Nature.

[58]  E. Wherry,et al.  Memory CD8 T-Cell Differentiation during Viral Infection , 2004, Journal of Virology.

[59]  K. Sugimoto,et al.  Suppression of HCV‐specific T cells without differential hierarchy demonstrated ex vivo in persistent HCV infection , 2003, Hepatology.

[60]  J. Sidney,et al.  Cellular immune selection with hepatitis C virus persistence in humans , 2005, The Journal of experimental medicine.

[61]  S. Lemon,et al.  Distinct Poly(I-C) and Virus-activated Signaling Pathways Leading to Interferon-β Production in Hepatocytes* , 2005, Journal of Biological Chemistry.

[62]  C. Rice,et al.  Normal functional capacity in circulating myeloid and plasmacytoid dendritic cells in patients with chronic hepatitis C. , 2005, The Journal of infectious diseases.

[63]  P. Klenerman,et al.  Immunity to hepatitis C virus: stunned but not defeated. , 2002, Microbes and infection.

[64]  B. Bartosch,et al.  Infectious Hepatitis C Virus Pseudo-particles Containing Functional E1–E2 Envelope Protein Complexes , 2003, The Journal of experimental medicine.

[65]  D. Barton,et al.  Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. , 2002, RNA.

[66]  Ronald N Germain,et al.  Cooperation between CD4+ and CD8+ T cells: when, where, and how. , 2006, Annual review of immunology.

[67]  C. Rice,et al.  Liver-Directed Gamma Interferon Gene Delivery in Chronic Hepatitis C , 2005, Journal of Virology.

[68]  I. N. Crispe,et al.  Hepatic T cells and liver tolerance , 2003, Nature Reviews Immunology.

[69]  B. Walker,et al.  Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. , 2003, The Journal of clinical investigation.

[70]  G. McCaughan,et al.  The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. , 2004, The Journal of clinical investigation.

[71]  C. Tseng,et al.  Binding of the Hepatitis C Virus Envelope Protein E2 to CD81 Inhibits Natural Killer Cell Functions , 2002, The Journal of experimental medicine.

[72]  M. Giménez-Barcons,et al.  The oncogenic potential of hepatitis C virus NS5A sequence variants is associated with PKR regulation. , 2005, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[73]  Takashi Taguchi,et al.  Hepatitis C virus NS5A protein interacts with 2',5'-oligoadenylate synthetase and inhibits antiviral activity of IFN in an IFN sensitivity-determining region-independent manner. , 2004, The Journal of general virology.

[74]  P. Klenerman,et al.  The dynamics of T‐lymphocyte responses during combination therapy for chronic hepatitis C virus infection , 2002, Hepatology.

[75]  G. Sen,et al.  Viruses and interferons. , 2001, Annual review of microbiology.

[76]  A. Weiner,et al.  Vaccination of chimpanzees against infection by the hepatitis C virus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[77]  N. Hayashi,et al.  Negative Regulation of NK Cell Activities by Inhibitory Receptor CD94/NKG2A Leads to Altered NK Cell-Induced Modulation of Dendritic Cell Functions in Chronic Hepatitis C Virus Infection1 , 2004, The Journal of Immunology.

[78]  J. Hoofnagle,et al.  Effects of antiviral therapy on the cellular immune response in acute hepatitis C , 2004, Hepatology.

[79]  A. Sette,et al.  Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. , 1997, The Journal of clinical investigation.

[80]  Todd M. Allen,et al.  CD8 Epitope Escape and Reversion in Acute HCV Infection , 2004, The Journal of experimental medicine.

[81]  A. Bertoletti,et al.  Heterologous T cell immunity in severe hepatitis C virus infection , 2005, The Journal of experimental medicine.

[82]  D. Vlahov,et al.  Protection against persistence of hepatitis C , 2002, The Lancet.

[83]  E. Wherry,et al.  Viral Persistence Alters CD8 T-Cell Immunodominance and Tissue Distribution and Results in Distinct Stages of Functional Impairment , 2003, Journal of Virology.

[84]  E. Keeffe,et al.  Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. , 2001, Blood.

[85]  C. Rice,et al.  Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees , 2004, Hepatology.

[86]  R. Bartenschlager Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture. , 2006, Current opinion in microbiology.

[87]  B. Walker,et al.  Broad Specificity of Virus-Specific CD4+ T-Helper-Cell Responses in Resolved Hepatitis C Virus Infection , 2002, Journal of Virology.

[88]  S. Friedman,et al.  Mechanisms of Disease: mechanisms of hepatic fibrosis and therapeutic implications , 2004, Nature Clinical Practice Gastroenterology &Hepatology.

[89]  C. Rice,et al.  Presence of functional dendritic cells in patients chronically infected with hepatitis C virus. , 2004, Blood.

[90]  H J Alter,et al.  The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. , 2000, Science.

[91]  Ralf Bartenschlager,et al.  Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus , 2005, Nature.

[92]  S. Ray,et al.  Humoral immune response in acute hepatitis C virus infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[93]  M. Gale,et al.  Evasion of intracellular host defence by hepatitis C virus , 2005, Nature.

[94]  P. Klenerman,et al.  Frequency and Phenotype of Circulating Vα24/Vβ11 Double-Positive Natural Killer T Cells during Hepatitis C Virus Infection , 2003, Journal of Virology.

[95]  M. Houghton,et al.  Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[96]  M. Kronenberg,et al.  Going both ways: immune regulation via CD1d-dependent NKT cells. , 2004, The Journal of clinical investigation.

[97]  T. Colby,et al.  Persistence of hepatitis C virus in patients successfully treated for chronic hepatitis C , 2005, Hepatology.

[98]  F. Weber,et al.  A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. , 2006, Antiviral research.

[99]  G. Freeman,et al.  Restoring function in exhausted CD8 T cells during chronic viral infection , 2006, Nature.

[100]  C. Walker,et al.  Cell-mediated immunity and the outcome of hepatitis C virus infection. , 2004, Annual review of microbiology.

[101]  T. Braciale,et al.  Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T-lymphocyte proliferation. , 2000, The Journal of clinical investigation.

[102]  M. Manns,et al.  Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C , 2000, Nature Medicine.

[103]  J. Ghrayeb,et al.  Memory CD8+ T Cells Are Required for Protection from Persistent Hepatitis C Virus Infection , 2003, The Journal of experimental medicine.

[104]  O. Hermine,et al.  Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. , 2006, Blood.

[105]  R. Purcell,et al.  Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti-HCV-positive plasma. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[106]  H. Ljunggren,et al.  Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance , 2000, Nature Medicine.

[107]  Salim I. Khakoo,et al.  HLA and NK Cell Inhibitory Receptor Genes in Resolving Hepatitis C Virus Infection , 2004, Science.

[108]  S. Ray,et al.  Cross-Genotype Immunity to Hepatitis C Virus , 2004, Journal of Virology.

[109]  R. Lanford,et al.  DNA Microarray Analysis of Chimpanzee Liver during Acute Resolving Hepatitis C Virus Infection , 2001, Journal of Virology.

[110]  C. Walker,et al.  Characterization of HCV‐specific Patr class II restricted CD4+ T cell responses in an acutely infected chimpanzee , 2003, Hepatology.

[111]  C. Rice,et al.  Neutralizing antibody response during acute and chronic hepatitis C virus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[112]  Rolf M. Zinkernagel,et al.  Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells , 1993, Nature.

[113]  F. Celada,et al.  Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. , 2006, The Journal of clinical investigation.

[114]  Charles M. Rice,et al.  HCV Persistence and Immune Evasion in the Absence of Memory T Cell Help , 2003, Science.

[115]  R. Ahmed,et al.  CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection , 1994, Journal of virology.

[116]  Jin-Xiong She,et al.  Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line , 2003, Hepatology.

[117]  A. J. McMichael,et al.  Immunology: The original sin of killer T cells , 1998, Nature.

[118]  M. Brunetto,et al.  Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donors. , 2005, Journal of hepatology.

[119]  D. Burton Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.

[120]  M. Gale,et al.  CARD games between virus and host get a new player. , 2006, Trends in immunology.

[121]  G. Leroux-Roels Development of prophylactic and therapeutic vaccines against hepatitis C virus , 2005, Expert review of vaccines.

[122]  B. Chain,et al.  Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? , 2005, The Lancet. Infectious diseases.

[123]  Spyros A. Kalams,et al.  The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses , 1998, The Journal of experimental medicine.

[124]  P. Simmonds,et al.  Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells. , 1998, The Journal of general virology.

[125]  M. Diago,et al.  Increased circulating and intrahepatic T‐cell‐specific chemokines in chronic hepatitis C: relationship with the type of virological response to peginterferon plus ribavirin combination therapy , 2004, Alimentary pharmacology & therapeutics.

[126]  Todd M. Allen,et al.  Broad Repertoire of the CD4+ Th Cell Response in Spontaneously Controlled Hepatitis C Virus Infection Includes Dominant and Highly Promiscuous Epitopes1 , 2005, The Journal of Immunology.

[127]  C. Rice,et al.  Lack of Phenotypic and Functional Impairment in Dendritic Cells from Chimpanzees Chronically Infected with Hepatitis C Virus , 2004, Journal of Virology.

[128]  D. Lavillette,et al.  Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee , 2005, Hepatology.

[129]  M. Lai,et al.  Hepatitis C Virus Infection Activates the Immunologic (Type II) Isoform of Nitric Oxide Synthase and Thereby Enhances DNA Damage and Mutations of Cellular Genes , 2004, Journal of Virology.

[130]  S. Lemon,et al.  Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[131]  C. Guha,et al.  Cell Culture Models and Animal Models of Viral Hepatitis. Part II: Hepatitis C , 2005, Lab Animal.

[132]  S. Kamal,et al.  Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C. , 2002, Gastroenterology.

[133]  D. Richman,et al.  Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections , 2002, Nature Medicine.

[134]  McCollum Rw The natural history of hepatitis. , 1969 .

[135]  N. Afdhal The natural history of hepatitis C. , 2004, Seminars in liver disease.

[136]  M. Lai,et al.  Establishment of B-Cell Lymphoma Cell Lines Persistently Infected with Hepatitis C Virus In Vivo and In Vitro: the Apoptotic Effects of Virus Infection , 2003, Journal of Virology.

[137]  B. Walker,et al.  Comprehensive Analysis of CD8+-T-Cell Responses against Hepatitis C Virus Reveals Multiple Unpredicted Specificities , 2002, Journal of Virology.

[138]  Alan S. Perelson,et al.  Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .

[139]  O. Schwartz,et al.  DC-SIGN and L-SIGN Are High Affinity Binding Receptors for Hepatitis C Virus Glycoprotein E2* , 2003, Journal of Biological Chemistry.

[140]  D. Stump,et al.  The hepatitis C virus alternate reading frame (ARF) and its family of novel products: the alternate reading frame protein/F-protein, the double-frameshift protein, and others. , 2005, Seminars in liver disease.

[141]  D. Ho,et al.  Diverse Hepatitis C Virus Glycoproteins Mediate Viral Infection in a CD81-Dependent Manner , 2004, Journal of Virology.

[142]  C. Walker,et al.  Adaptive immune responses in acute and chronic hepatitis C virus infection , 2005, Nature.

[143]  A. Hughes,et al.  The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. , 2001, Immunity.

[144]  K. Shimotohno,et al.  Effects of Mutation in Hepatitis C Virus Nonstructural Protein 5A on Interferon Resistance Mediated by Inhibition of PKR Kinase Activity in Mammalian Cells , 2001, Microbiology and immunology.

[145]  B. Walker,et al.  Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus , 2000, The Journal of experimental medicine.

[146]  M. Houghton,et al.  Effects of interferon treatment on the antiviral T‐cell response in hepatitis C virus genotype 1b‐ and genotype 2c‐infected patients , 1997, Hepatology.

[147]  F. Chisari,et al.  Blocking Chemokine Responsive to γ–2/Interferon (IFN)-γ Inducible Protein and Monokine Induced by IFN-γ Activity In Vivo Reduces the Pathogenetic but not the Antiviral Potential of Hepatitis B Virus–specific Cytotoxic T Lymphocytes , 2001, The Journal of experimental medicine.

[148]  J. McHutchison,et al.  American Gastroenterological Association technical review on the management of hepatitis C. , 2006, Gastroenterology.

[149]  H. Blum,et al.  T Cells with a CD4+CD25+ Regulatory Phenotype Suppress In Vitro Proliferation of Virus-Specific CD8+ T Cells during Chronic Hepatitis C Virus Infection , 2005, Journal of Virology.

[150]  P. Parham NK Cells Lose Their Inhibition , 2004, Science.

[151]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[152]  F. Chisari,et al.  Stealth and Cunning: Hepatitis B and Hepatitis C Viruses , 2005, Journal of Virology.

[153]  T. Salazar-Mather,et al.  Cytokine and chemokine networks: pathways to antiviral defense. , 2006, Current topics in microbiology and immunology.

[154]  T. Santantonio,et al.  Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C. , 1999, Gastroenterology.

[155]  A. Perelson,et al.  Viral dynamics and response differences in HCV‐infected African American and white patients treated with IFN and ribavirin , 2003, Hepatology.

[156]  P Parham,et al.  Analysis of a successful immune response against hepatitis C virus. , 1999, Immunity.

[157]  Ralf Bartenschlager,et al.  Novel insights into hepatitis C virus replication and persistence. , 2004, Advances in virus research.

[158]  Roger Williams,et al.  Hepatitis C virus-specific T-cell reactivity during interferon and ribavirin treatment in chronic hepatitis C. , 2000, Gastroenterology.

[159]  F. Chisari,et al.  Noncytolytic control of viral infections by the innate and adaptive immune response. , 2001, Annual review of immunology.

[160]  J. Hiscott,et al.  MasterCARD: a priceless link to innate immunity. , 2006, Trends in molecular medicine.

[161]  Ruslan Medzhitov,et al.  Toll Pathway-Dependent Blockade of CD4+CD25+ T Cell-Mediated Suppression by Dendritic Cells , 2003, Science.

[162]  Zhijian J. Chen,et al.  Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[163]  F. Zoulim,et al.  Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. , 2001, Gastroenterology.

[164]  S. Nuti,et al.  Inhibition of Natural Killer Cells through Engagement of CD81 by the Major Hepatitis C Virus Envelope Protein , 2002, The Journal of experimental medicine.

[165]  C. Cheng‐Mayer,et al.  Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[166]  W. Olson,et al.  L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[167]  J. Heathcote,et al.  Treatment of hepatitis C , 2005, Journal of viral hepatitis.

[168]  S. Emerson,et al.  In vitro assay for neutralizing antibody to hepatitis C virus: Evidence for broadly conserved neutralization epitopes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[169]  J. Piette,et al.  CD4+CD25+ regulatory T-cell deficiency in patients with hepatitis C-mixed cryoglobulinemia vasculitis. , 2004, Blood.

[170]  B. Rehermann,et al.  Immunology of hepatitis B virus and hepatitis C virus infection , 2005, Nature Reviews Immunology.

[171]  R. Purcell,et al.  Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[172]  S. Emerson,et al.  Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[173]  C. Rice,et al.  Previously Infected and Recovered Chimpanzees Exhibit Rapid Responses That Control Hepatitis C Virus Replication upon Rechallenge , 2002, Journal of Virology.